New developments in the management of cytomegalovirus infection after solid organ transplantation

Drugs

Volumn 70, Issue 8, 2010, Pages 965-981

  Eid, Albert J ^a   Razonable, Raymund R ^b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Cidofovir; Cytomegalovirus infections; Foscarnet; Ganciclovir; Maribavir; Prevention; Research and development; Therapeutic use; Transplantation; Treatment

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ALVAC CMV VACCINE; ANTIVIRUS AGENT; ARTESUNATE; BENZIMIDAVIR; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; CYTOMEGALOVIRUS ANTIGEN PP65; CYTOMEGALOVIRUS VACCINE; EVEROLIMUS; FOSCARNET; GANCICLOVIR; GB VACCINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PLACEBO; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VALACICLOVIR; VALGANCICLOVIR; VCL CB01 VACCINE; VCL CT02 VACCINE;

ACUTE GRAFT REJECTION; ADD ON THERAPY; BACTERIAL INFECTION; BRONCHIOLITIS OBLITERANS; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FIBROSIS; GRAFT FAILURE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; INFECTION PREVENTION; INTESTINE TRANSPLANTATION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PROTOZOAL INFECTION; REVIEW; RISK FACTOR; TRANSPLANT VASCULOPATHY; TREATMENT DURATION; TUBULOINTERSTITIAL FIBROSIS; UNSPECIFIED SIDE EFFECT;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; HUMANS; IMMUNOCOMPROMISED HOST; ORGAN TRANSPLANTATION; RISK FACTORS;

CYTOMEGALOVIRUS;

EID: 77952610548     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/10898540-000000000-00000     Document Type: Review

References (91)

1. Slifkin M, Doron S, Snydman DR. Viral prophylaxis in or-gan transplant patients. Drugs 2004; 64 (24): 2763-2792
2. Limaye AP, Bakthavatsalam R, Kim HW, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006; 81 (12): 1645-1652
3. Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008; 46 (6): 840-846
4. Razonable RR, Paya CV. Herpes virus infections in trans-plant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 2003; 10 (3): 60-65
5. Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl 2007; 13 (12): 1703-1709
6. Kijpittayarit-Arthurs S, Eid AJ, Kremers WK, et al. Clinical features and outcomes of delayed-onset primary cytome-galovirus disease in cardiac transplant recipients. J Heart Lung Transplant 2007; 26 (10): 1019-1024
7. Scemla A, Kreis H, Legendre C. Less pessimistic long-term results for patients with cytomegalovirus disease. Clin Infect Dis 2008; 47 (10): 1360-1; author reply 1361-1362
8. Kumar D, Chernenko S, Moussa G, et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009; 9 (5): 1214-1222
9. Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infec-tions in 547 organ transplant recipients receiving alem-tuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007; 44 (2): 204-212
10. Zeevi A, Husain S, Spichty KJ, et al. Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab. Am J Transplant 2007; 7 (2): 471-475
11. Hoppe L, Marroni CA, Bressane R, et al. Risk factors associated with cytomegalovirus infection in orthotopic liver transplant patients. Transplant Proc 2006;38 (6): 1922-1923
12. Song AT, Abdala E, Bonazzi PR, et al. Does mycophenolate mofetil increase the risk of cytomegalovirus infection in solid organ transplant recipients? A mini-review. Braz J Infect Dis 2006; 10 (2): 132-138
13. Razonable RR, Rivero A, Rodriguez A, et al. Allograft re-jection predicts the occurrence of late-onset cytomegalo-virus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganci-clovir. J Infect Dis 2001; 184 (11): 1461-1464
14. Reusser P, Cathomas G, Attenhofer R, et al. Cytomegalo-virus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J Infect Dis 1999; 180 (2): 247-253
15. Sester M, Sester U, Gartner B, et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 2001; 71 (9): 1287-1294
16. Tu W, Potena L, Stepick-Biek P, et al. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allo-graft disease. Circulation 2006; 114 (15): 1608-1615
17. Gerna G, Lilleri D, Fornara C, et al. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transplant 2006; 6 (10): 2356-2364
18. Eid AJ, Brown RA, Arthurs SK, et al. A prospective long-itudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection. Transpl Int. Epub 2009 Nov 27
19. La Rosa C, Limaye AP, Krishnan A, et al. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis 2007; 195 (5): 633-644
20. Kijpittayarit S, Eid AJ, Brown RA, et al. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Clin Infect Dis 2007; 44 (10): 1315-1320
21. Ducloux D, Deschamps M, Yannaraki M, et al. Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney Int 2005; 67 (6): 2454-2461
22. Cervera C, Lozano F, Saval N, et al. The influence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation 2007; 83 (11): 1493-1500
23. Manuel O, Pascual M, Trendelenburg M, et al. Association between mannose-binding lectin deficiency and cytomega-lovirus infection after kidney transplantation. Transplantation 2007; 83 (3): 359-362
24. Loeffler J, Steffens M, Arlt EM, et al. Polymorphisms in the genes encoding chemokine receptor 5, interleukin-10, and monocyte chemoattractant protein 1 contribute to cyto-megalovirus reactivation and disease after allogeneic stem cell transplantation. J Clin Microbiol 2006; 44 (5): 1847-1850
25. Eid AJ, Arthurs SK, Deziel PJ, et al. Clinical predictors of relapse after treatment of primary gastrointestinal cyto-megalovirus disease in solid organ transplant recipients. Am J Transplant 2010 Jan; 10 (1): 157-161
26. Eid AJ, Bakri SJ, Kijpittayarit S, et al. Clinical features and outcomes of cytomegalovirus retinitis after transplantation. Transpl Infect Dis 2008 Feb; 10 (1): 13-18
27. Razonable RR, Brown RA, Humar A, et al. A longitudinal molecular surveillance study of human polyomavirus vir-emia in heart, kidney, liver, and pancreas transplant patients. J Infect Dis 2005; 192 (8): 1349-1354
28. Razonable RR, Paya CV. The impact of human herpesvirus-6 and-7 infection on the outcome of liver transplantation. Liver Transpl 2002; 8 (8): 651-658
29. Razonable RR, Rivero A, Brown RA, et al. Detection of simultaneous beta-herpesvirus infections in clinical syndromes due to defined cytomegalovirus infection. Clin Transplant 2003; 17 (2): 114-120
30. Peleg AY, Husain S, Qureshi ZA, et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007; 44 (10): 1307-1314
31. Husni RN, Gordon SM, Longworth DL, et al. Cytomega-lovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 1998; 26 (3): 753-755
32. Razonable RR, Burak KW, van Cruijsen H, et al. The pa-thogenesis of hepatitis C virus is influenced by cytomega-lovirus. Clin Infect Dis 2002; 35 (8): 974-981
33. Nebbia G, Mattes FM, Cholongitas E, et al. Exploring the bidirectional interactions between human cytomegalovirus and hepatitis C virus replication after liver transplantation. Liver Transpl 2007; 13 (1): 130-135
34. Fearon WF, Potena L, Hirohata A, et al. Changes in cor-onary arterial dimensions early after cardiac transplantation. Transplantation 2007; 83 (6): 700-705
35. Hussain T, Burch M, Fenton MJ, et al. Positive pre-transplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children. Circulation 2007; 115 (13): 1798-1805
36. Ozdemir FN, Akgul A, Altunoglu A, et al. The association between cytomegalovirus infection and atherosclerotic events in renal transplant recipients. Transplant Proc 2007; 39 (4): 990-992
37. Thomas LD, Milstone AP, Miller GG, et al. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganci-clovir regimen. Clin Transplant 2009; 23 (4): 476-483
38. Rodrigo E, Fernandez-Fresnedo G, Valero R, et al. New-onset diabetes after kidney transplantation: risk factors. J Am Soc Nephrol 2006; 17 (12 Suppl. 3): S291-5
39. Hartmann A, Sagedal S, Hjelmesaeth J. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation 2006; 82 (2 Suppl.): S15-7
40. Couzi L, Levaillant Y, Jamai A, et al. Cytomegalovirus-induced gammadelta T cells associate with reduced cancer risk after kidney transplantation. J Am Soc Nephrol 2010 Jan; 21 (1): 181-188
41. Sagedal S, Rollag H, Hartmann A. Cytomegalovirus infec-tion in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk. Clin Transplant 2007; 21 (3): 309-313
42. Helantera I, Koskinen P, Finne P, et al. Persistent cytome-galovirus infection in kidney allografts is associated with inferior graft function and survival. Transpl Int 2006; 19 (11): 893-900
43. Potena L, Holweg CT, Chin C, et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 2006; 82 (3): 398-405 (Pubitemid 44223041)
44. Hellinger WC, Bonatti H, Machicao VI, et al. Effect of anti-viral chemoprophylaxis on adverse clinical outcomes associated with cytomegalovirus after liver transplantation. Mayo Clin Proc 2006; 81 (8): 1029-1033
45. Manuel O, Kumar D, Moussa G, et al. Lack of association between beta-herpesvirus infection and bronchiolitis ob-literans syndrome in lung transplant recipients in the era of antiviral prophylaxis. Transplantation 2009; 87 (5): 719-725
46. Hodson EM, Jones CA, Webster AC, et al. Antiviral medi-cations to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365 (9477): 2105-2115
47. Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytome-galovirus in solid organ transplant recipients. Ann Intern Med 2005; 143 (12): 870-880
48. Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl. 4: S78-86
49. Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006; 43 (7): 869-880
50. Hodson EM, Jones CA, Strippoli GF, et al. Immuno-globulins, vaccines or interferon for preventing cytomega-lovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2007; (2): CD005129
51. Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res 2009 May; 82 (2): A84-98
52. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4 (4): 611-620
53. Humar A, Kumar D, Preiksaitis J, et al. A trial of valgan-ciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant 2005; 5 (6): 1462-1468
54. Drew WL, Miner RC, Marousek GI, et al. Maribavir sen-sitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol 2006; 37 (2): 124-127
55. Winston DJ, Young JA, Pullarkat V, et al. Maribavir pro-phylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008; 111 (11): 5403-5410
56. Walker JK, Scholz LM, Scheetz MH, et al. Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction. Transplantation 2007; 83 (7): 874-882
57. Doyle AM, Warburton KM, Goral S, et al. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course. Transplantation 2006; 81 (8): 1106-1111
58. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. In Press
59. San Juan R, Yebra M, Lumbreras C, et al. A new strategy of delayed long-term prophylaxis could prevent cytomegalo-virus disease in (D+/R-) solid organ transplant recipients. Clin Transplant 2009; 23 (5): 666-671
60. Razonable RR, van Cruijsen H, Brown RA, et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis 2003; 187 (11): 1801-1808
61. Paya CV, Wilson JA, Espy MJ, et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 2002; 185 (7): 854-860
62. Emery VC, Hassan-Walker AF, Burroughs AK, et al. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and-experienced immunocompromised hosts. J Infect Dis 2002; 185 (12): 1723-1728
63. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cyto-megalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6 (9): 2134-2143
64. Lopau K, Greser A, Wanner C. Efficacy and safety of pre-emptive anti-CMV therapy with valganciclovir after kidney transplantation. Clin Transplant 2007; 21 (1): 80-85
65. Diaz-Pedroche C, Lumbreras C, San Juan R, et al. Valgan-ciclovir preemptive therapy for the prevention of cyto-megalovirus disease in high-risk seropositive solid-organ transplant recipients. Transplantation 2006; 82 (1): 30-35
66. Mattes FM, Hainsworth EG, Hassan-Walker AF, et al. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with val-ganciclovir. J Infect Dis 2005; 191 (1): 89-92
67. Humar A, Siegal D, Moussa G, et al. A prospective assess-ment of valganciclovir for the treatment of cytomegalo-virus infection and disease in transplant recipients. J Infect Dis 2005; 192 (7): 1154-1157
68. Asberg A, Humar A, Rollag H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7 (9): 2106-2113
69. Asberg A, Humar A, Jardine AG, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009; 9 (5): 1205-1213
70. Humar A, Kumar D, Boivin G, et al. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002; 186 (6): 829-833
71. Sia IG, Wilson JA, Groettum CM, et al. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000; 181 (2): 717-720
72. Fica A, Cervera C, Perez N, et al. Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests. Transpl Infect Dis 2007; 9 (3): 203-210
73. Nogueira E, Ozaki KS, Tomiyama H, et al. The emergence of cytomegalovirus resistance to ganciclovir therapy in kidney transplant recipients. Int Immunopharmacol 2006; 6 (13-14): 2031-2037
74. Limaye AP. Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients. Semin Respir Infect 2002; 17 (4): 265-273
75. Limaye AP, Raghu G, Koelle DM, et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185 (1): 20-27
76. Boivin G, Goyette N, Gilbert C, et al. Analysis of cytome-galovirus DNA polymerase (UL54) mutations in solid organ transplant patients receiving valganciclovir or gan-ciclovir prophylaxis. J Med Virol 2005; 77 (3): 425-429
77. Boivin G, Gilbert C, Gaudreau A, et al. Rate of emergence of cytomegalovirus (CMV) mutationsinleukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J Infect Dis 2001; 184 (12): 1598-1602
78. Mendez JC, Sia IG, Tau KR, et al. Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy. Transplantation 1999; 67 (5): 755-757
79. Eid AJ, Arthurs SK, Deziel PJ, et al. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008; 22 (2): 162-170
80. Battiwalla M, Paplham P, Almyroudis NG, et al. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. Transpl Infect Dis 2007; 9 (1): 28-32
81. Efferth T, Romero MR, Wolf DG, et al. The antiviral ac-tivities of artemisinin and artesunate. Clin Infect Dis 2008; 47 (6): 804-811
82. Shapira MY, Resnick IB, Chou S, et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis 2008; 46 (9): 1455-1457
83. Levi ME, Mandava N, Chan LK, et al. Treatment of multi-drug-resistant cytomegalovirus retinitis with systemically administered leflunomide. Transpl Infect Dis 2006; 8 (1): 38-43
84. Hill JA, Hummel M, Starling RC, et al. A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 2007; 84 (11): 1436-1442
85. San Juan R, Aguado JM, Lumbreras C, et al. Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis 2008; 47 (7): 875-882
86. Razonable RR. Immune-based therapies for cytomegalo-virus infection. Immunotherapy 2010; 2 (1): 117-130
87. Plotkin SA, Smiley ML, Friedman HM, et al. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet 1984; 1 (8376): 528-530
88. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetra-mers. J Exp Med 2005; 202 (3): 379-386
89. Bao L, Dunham K, Stamer M, et al. Expansion of cytome-galovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008; 14 (10): 1156-1162
90. Slavin S. Adoptive immunotherapy for CMV disease [Clin-icalTrials.gov identifier NCT00159055]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Mar 23]
91. Lucas KG. Vaccine therapy in treating patients who have undergone a donor stem cell transplant and have cytome-galovirus infection that has not responded to therapy [ClinicalTrials.gov identifier NCT00509691]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2010 Mar 23]